Breaking News

ChemDiv Earns Lilly Milestones

December 19, 2012

Identifies multiple active series to supplement Lilly programs

ChemDiv, Inc., a drug discovery and development CRO, has received several milestones across three therapeutic areas under its collaboration with Eli Lilly. Financial details were not disclosed.
Alex Kiselyov, Ph.D., president of ChemDiv, said, "Using our integrated drug discovery platforms, a team of chemists and biologists at ChemDiv identified multiple active series to supplement therapeutic programs at Eli Lilly. This is yet another step in our successful collaborative efforts with pharma and biotech partners to identify advanced preclinical drug candidates."

Related Contract Manufacturing:

Related Compliance: